5.3.5 Summary of evidence and guidelines for staging of prostate cancer,
Recommendations  Strength rating,
Offer a watchful waiting policy to asymptomatic patients with clinically localised   Strong  disease and with a life expectancy < 10 years (based on co-morbidities and age).,
Surgical treatment,
Radical prostatectomy (RP) can be safely delayed for at least 3 months from   Weak  diagnosis in any risk category.,
"When a lymph node dissection (LND) is deemed necessary based on a nomogram,   Strong  perform an extended LND template for optimal staging.",
Radiotherapeutic treatment,
Offer moderate hypofractionation (HFX) with IMRT/VMAT plus IGRT to the prostate   to patients with localised disease (60 Gy/20 fractions in 4 weeks or 70 Gy/28   fractions in 6 weeks).,Strong
Offer low-dose rate (LDR) brachytherapy monotherapy to patients with good urinary   function and low-risk or NCCN favourable intermediate-risk disease.,Strong
Offer LDR or high-dose rate (HDR) brachytherapy boost combined with IMRT/  VMAT plus IGRT to patients with good urinary function and NCCN unfavourable   intermediate-risk or high-risk disease and/or locally-advanced disease.,Weak
Active therapeutic options outside surgery or radiotherapy,
Only offer focal therapy with high-intensity focused ultrasound or cryotherapy within   Strong  a clinical trial or prospective registry.,
